Rhabdomyolysis Associated with Simvamtatin-Nefazodone Therapy

Maryann Z. Skrabal, Julie A. Stading, Michael S. Monaghan

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Simvastatin is a hydroxymethyl glutaryl coenzyme A reductase inhibitor commonly used to treat patients with hyperlipidemia. It is a safe and effective medication in most patients when used appropriately. A serious side effect known as rhabdomyolysis may rarely occur in patients who take simvastatin, especially at higher doses and with agents that interact and increase the level of simvastatin in the blood. We describe the case of a patient with rhabdomyolysis that occurred after the patient's simvastatin was titrated to 80 mg at approximately the same time that his antidepressant medication was switched to nefazodone. We found only two other similar cases in the literature, both of which were presented as letters to the editor in two different journals. We present this case to add to the literature and to assist practitioners by raising their awareness of this interaction so that it can be monitored.

Original languageEnglish (US)
Pages (from-to)1034-1035
Number of pages2
JournalSouthern Medical Journal
Issue number10
StatePublished - Oct 1 2003

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Rhabdomyolysis Associated with Simvamtatin-Nefazodone Therapy'. Together they form a unique fingerprint.

Cite this